-+ 0.00%
-+ 0.00%
-+ 0.00%

SpyGlass Pharma Announces Positive Topline 1/2 Trial Results For BIM-IOL Intracranial Pressure Treatment

Benzinga·03/09/2026 12:06:53
Listen to the news

12-month results from the Phase 1/2 trial evaluating its lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), for the treatment of elevated intraocular pressure (IOP) in patients previously diagnosed with open-angle glaucoma (OAG) or ocular hypertension (OHT) and a concomitant cataract.